What is Otalgan?
Otalgan topical jelly or ointment is used on different parts of the body to cause numbness or loss of feeling for patients having certain medical procedures. It is also used to relieve pain and itching caused by conditions such as sunburn or other minor burns, insect bites or stings, poison ivy, poison oak, poison sumac, minor cuts, or scratches.
Otalgan viscous topical solution is also used to treat sore mouth or throat and also reduce gagging during the taking of X-ray pictures and dental impressions.
Otalgan skin patch is used to relieve pain caused by shingles (postherpetic neuralgia).
Otalgan belongs to the family of medicines called local anesthetics. Otalgan prevents pain by blocking the signals at the nerve endings in the skin. Otalgan does not cause unconsciousness as general anesthetics do when used for surgery.
Otalgan is available only with your doctor's prescription.
Otalgan indications
Otalgan (Otalgan HCl) Injections are indicated for production of local or regioinal anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
How should I use Otalgan?
Use Otalgan as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Wash your hands well before and after using Otalgan.
- Shake well before each use.
- If you are using Otalgan on your face, spray it into your hand. Gently apply. Do not spray Otalgan directly onto your face.
- For other areas, hold the medicine 4 to 6 inches from the skin and spray onto the affected area. Allow the medicine to slowly dry.
- Do not use large amounts of Otalgan, especially over blistered or raw areas of your skin.
- Do not bandage or wrap the affected area, unless directed otherwise by your doctor.
- If you miss a dose of Otalgan, use it as soon as you remember. Continue to use it as directed by your doctor or on the package label.
Ask your health care provider any questions you may have about how to use Otalgan.
Uses of Otalgan in details
How to use Otalgan topical
Otalgan description
Each gram contains Lidocaine 50 mg equivalent to Otalgan 700 mg per 10 cm x 14 cm medicated plaster.
It also contains the following excipients: Self-Adhesive Layer: Glycerol, liquid sorbitol (crystallizing), carmellose sodium, propylene glycol (E1520), urea, heavy kaolin, tartaric acid, gelatin, polyvinyl alcohol, aluminum glycinate, disodium edetate, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), polyacrylic acid, sodium polyacrylate, purified water.
Backing Fabric and Release Liner: Polyethylene terephthalate (PET).
Otalgan dosage
Otalgan Dosage
Generic name: Otalgan
Dosage form: Transoral Delivery System
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
When the Otalgan® system is used concomitantly with other products containing Otalgan, the total dose contributed by all formulations must be kept in mind.
Isolate the procedure area with cotton rolls and use suction as appropriate. Dry the tissue with air or gauze. Remove the Otalgan® system from its packaging and peel off the clear protective liner. Immediately apply the Otalgan® system using firm pressure. Allow the patch to remain in place until the desired anesthetic effect is produced but not for longer than 15 minutes. Experience in children is inadequate to recommend a pediatric dose at this time.
More about Otalgan (Otalgan)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Other brands: Nervocaine, UAD Caine, Truxacaine, Otalgan HCl, More (4) »
Professional resources
- Otalgan (FDA)
- Otalgan Hydrochloride (Local) (AHFS Monograph)
Related treatment guides
- Anesthesia
- Arrhythmia
- Burning Mouth Syndrome
- Ventricular Fibrillation
- Ventricular Tachycardia
Otalgan interactions
See also:
What other drugs will affect Otalgan?
Beta-blockers increase the risk of bradycardia and hypotension. Norepinephrine and beta-blockers by reducing hepatic blood flow decrease (increased toxicity), isadrine and glucagon - increase the clearance of Otalgan. Cimetidine increases the plasma concentration of Otalgan Haffkine Bio-Pharmaceutical Corporation (displaces from its association with proteins and slows inactivation in the liver). Barbiturates causing induction of microsomal enzymes stimulate the degradation of Otalgan and reduce its activity. Anticonvulsants (hydantoin derivatives) accelerate the biotransformation in the liver (decreased concentration in the blood), for IV injections it may increases cardiodepressive action of Otalgan. Antiarrhythmics (amiodarone, verapamil, quinidine, aymalin) potentiate cardiac depression. Combination with novocainamide may cause CNS excitement and hallucinations. Otalgan Haffkine Bio-Pharmaceutical Corporation strengthens the inhibitory effect of anesthesia (hexobarbital, thiopental sodium), hypnotics and sedatives on the respiratory center, weakens the cardiac effects of digitoxin, enhances muscle relaxation caused by drugs curare like (possible paralysis of respiratory muscles). MAO inhibitors prolong local anesthesia.
Otalgan side effects
See also:
What are the possible side effects of Otalgan?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of Otalgan™ has been evaluated in 10 clinical trials, five in adults and five in pediatric patients.
The five adult clinical trials consisted of a randomized, double-blind, parallel-arm, sham-placebo controlled Phase 3 trial that enrolled 693 patients, two randomized, double-blind, crossover design, sham-placebo controlled Phase 1 trials that enrolled 455 patients, and two open-label studies that enrolled 44 patients. A total of 742 adults received an active treatment with an active treatment that delivered a 0.5 mg dose of Otalgan, while 775 received placebo.
The five pediatric clinical trials consisted of five randomized, double-blind, parallel-arm, sham-placebo controlled trials in which 1761 patients, ages 3 to 18, received either Otalgan™ or a sham placebo device. A total of 906 pediatric patients received active treatment, while 855 received placebo.
Application Site Reaction
The application site was specifically assessed for four categories of skin site reaction (erythema, edema, pruritus, and petechiae).
In adults, erythema occurred in 67.3% of Otalgan™-treated patients, and in 25.0% of placebo-treated patients. Petechiae occurred in 46.4% of Otalgan™-treated patients, and in 7.0% of placebo-treated patients. Edema occurred in 4.3% of Otalgan™-treated patients, and in 0.8% of placebo-treated patients. Pruritus occurred in 9.4% of Otalgan™-treated patients and in 6.2% of placebo-treated patients.
In pediatric patients, erythema occurred in 53% of Otalgan-treated patients, and in 27% of placebo-treated patients. Petechiae occurred in 44% of Otalgan-treated patients, and in 5% of placebo-treated patients. Edema occurred in 8% of Otalgan-treated patients, and in 3% of placebo-treated patients. Pruritus occurred in 1% of patients in both treatment groups.
Adverse Reactions
Amongst the 742 adult patients receiving active treatment and 775 adult patients receiving sham placebo treatment in the 5 adult studies, the percentage of adult patients with any adverse reactions was 3.9% in the active-treated patients and 4.9% in the sham placebo treated patients.
Most adverse reactions were application-site related (i.e., hypoaesthesia (0% active, 0.5% sham placebo), burning (0.54% active, 0.4% sham placebo), and venipuncture site hemorrhage (0.4% active, 1.7% sham placebo)).
The most common systemic adverse reaction was dizziness, which occurred in 0.9% of active-treated adult patients and in 0.7% of sham placebo treated adult patients. No other systemic adverse events occurred in more than two patients in either treatment group.
Amongst the 906 pediatric patients receiving active treatment and 855 pediatric patients receiving sham placebo treatment, the percentage of pediatric patients with any adverse reactions was approximately 9% in each treatment group.
Most adverse reactions were application-site related (i.e., bruising, burning, pain, contusion, hemorrhage), occurring in 4% of pediatric patients in each treatment group.
The most common systemic adverse reactions were nausea (2%) and vomiting (1%).
Otalgan contraindications
See also:
What is the most important information I should know about Otalgan?
You should not receive this medication if you are allergic to Otalgan or any other type of numbing medicine.
Before you receive Otalgan injection, tell your doctor if you have liver or kidney disease, heart disease, coronary artery disease, circulation problems, or a history of malignant hyperthermia.
To treat irregular heart rhythms, your doctor may prescribe a LidoPen auto-injector. This is a prefilled automatic injection device to be used in an emergency. Keep the device with you at all times.
Your doctor will describe the signs and symptoms to watch for when deciding when it's time to use Otalgan injection at home. Never use the LidoPen auto-injector without first calling your doctor.
With the LidoPen auto-injector you will also receive a CardioBeeper to transmit your heart rate and rhythm to your doctor over a telephone. Read all provided instructions and practice using the CardioBeeper.
Otalgan can cause side effects that may impair your thinking or reactions. Unless absolutely necessary, do not drive after using this medication
Active ingredient matches for Otalgan:
Lidocaine in Austria, Belgium, Germany, Italy, Netherlands, Switzerland.
Chloramphenicol/Phenazone/Prednisolone Acetate/Procaine Hcl
Chloramphenicol/prednisolone in Mexico.
Lidocaine hydrochloride in Netherlands.
Lidocaine hydrochloride/Phenazone in Austria.
Phenazone/Procaine in Germany, Italy, Switzerland.
Phenazone/Procaine hydrochloride in Switzerland.
Unit description / dosage (Manufacturer) | Price, USD |
Drops; Otic; Phenazone 5%; Procaine Hydrochloride 1% | |
Drops; Otic; Lidocaine Hydrochloride; Phenazone | |
List of Otalgan substitutes (brand and generic names): | |
OSSILEX AC | |
Ossilex AC Drop (Stadchem Of India) | $ 0.26 |
Otek AC (Oman) | |
Otipax 1% (Belgium) | |
Otipax L (Slovakia) | |
Otocalmine 2% (Belgium, Luxembourg) | |
Otolab (Germany) | |
Otomidone (Italy) | |
Otopax (Italy) | |
Otopax Ear 5 ml Drop (Baxter (India) Pvt. Ltd.) | $ 0.33 |
Otoralgyl (Belgium) | |
Otoraz | |
Otosan (Switzerland) | |
Drops; Otic; Phenazone 5%; Procaine Hydrochloride 1% (Streuli) | |
Otosedol (Spain) | |
Otosmo (Spain) | |
Otovin | |
P.COL | |
P.COL DROPS 1 packet / 5 ML drop each (Optho Remedies Pvt Ltd) | $ 0.30 |
P.Col Drop (Optho Remedies Pvt Ltd) | $ 0.30 |
Partran (Japan) | |
Partran 2% (Japan) | |
Partran 8% (Japan) | |
Pediatric LTA Kit | |
Solution; Topical; Lidocaine Hydrochloride 2% | |
Penles (Japan) | |
Pensacaine with Adrenaline (United Kingdom) | |
Percutaneous Sheath Introducer Kit HL-09883 | |
Injectable; Injection; Lidocaine Hydrochloride 1% | |
Percutaneous Sheath Introducer Kit Hl-09883 liquid 1 % (Arrow International Inc. (Canada)) | |
Peterkaien | |
Peterkaïen (South Africa) | |
Pharmacaine (Mexico) | |
Pharmaniaga Lignocaine HCl (Malaysia) | |
Pharmaniaga Lignocaine HCl 2% w/v 10 mL x 10 x 1's (Pharmaniaga Manufacturing Berhad) | |
Phenazone/Procaine (Germany, Italy, Switzerland) | |
phenazone/Procaine hydrochloride | |
Phil Pharmawealth/Atlantic Lidocaine (Philippines) | |
Phil Pharmawealth/Atlantic Lidocaine / amp 2 % x 5 mL x 25's (Atlantic Lab) | |
Phil Pharmawealth/Atlantic Lidocaine 2 % x 50's (Atlantic Lab) | |
Phil Pharmawealth/Atlantic Lidocaine / vial 2 % x 50 mL x 10's (Atlantic Lab) | |
Phil Pharmawealth/Atlantic Lidocaine 2 % x 25's (Atlantic Lab) | |
Phil Pharmawealth/Atlantic Lidocaine inj 2 % 50 mL x 25 x 1's (Atlantic Lab) | |
Plidocain (Poland) | |
PMS-Lidocaine (Canada) | |
PMS-Lidocaine Viscous (Hong Kong) | |
Liquid; Dental; Lidocaine Hydrochloride 2% | |
PMS-Lidocaine Viscous 2 % x 100 mL | |
Positex (Germany) | |
See 2090 substitutes for Otalgan |
References
- DailyMed. "PREDNISOLONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "LIDOCAINE; TETRACAINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CHLORAMPHENICOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Otalgan are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Otalgan. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
Users | % | ||
---|---|---|---|
16-29 | 1 | 100.0% |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology